NCT07161323

Brief Summary

This study is designed as a crossover trial. All participants who meet the inclusion criteria and voluntarily agree to participate will be evaluated using the assessment methods detailed below. Subsequently, participants will be randomly assigned into two groups. The first group (Mulligan Concept Group - MCG) will receive the SNAG technique, while the second group (Neural Mobilization Group - NMG) will perform the Sciatic Nerve Mobilization Exercise (SNME). After the intervention, participants will be evaluated a second time. Ten days after this session, participants will be invited back. Those who were in the MCG group during the first session will be re-evaluated and then receive the SNGE intervention. Participants who were in the SNGE group during the first session will be re-evaluated and then receive the SNAG intervention. Following this second intervention, participants will be evaluated once again. Assessments will be done are Demographic Form, Visual Analogue Scale, Oswestry Disability Index, Joint Range of Motion, Five-times Sit-to-stand Test, Sit and Reach Test

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
2mo left

Started Jul 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress85%
Jul 2025Jul 2026

Study Start

First participant enrolled

July 1, 2025

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

July 30, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 8, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

September 8, 2025

Status Verified

September 1, 2025

Enrollment Period

1 year

First QC Date

July 30, 2025

Last Update Submit

September 1, 2025

Conditions

Keywords

Sciatic Nerve PainMulligan ConceptManual TherapyPain ManagementNon-Specific Sciatica

Outcome Measures

Primary Outcomes (3)

  • Oswestry Disability Index (ODI)

    The ODI assesses the impact of sciatic nerve pain on daily activities, including sitting, standing, walking, sleeping, and personal care. The total score indicates the level of disability.

    Through study completion, an average of 1 year

  • 5 Times Sit to Stand Test

    The test will be used to measure the time it takes for an individual to rise from a seated position and sit back down. The participant is prepared in a seated position on a standard chair with a height of 43-46 cm, with their back against the chair and arms crossed over the chest. Upon the command to begin, the participant stands up fully and then completes the test by sitting down and standing up a total of five times as quickly as possible.

    Through study completion, an average of 1 year

  • Sit and Reach Test

    The participant will sit on a mat placed on a flat surface, with legs extended straight forward and knees fully extended. The soles of the feet will be positioned vertically and kept stable. The participant will then reach forward with both arms, aiming to touch the toes or reach beyond them if possible. The reach distance will be recorded in centimeters based on how far the fingertips are from the soles of the feet.

    Through study completion, an average of 1 year

Secondary Outcomes (2)

  • Range of Motion

    Through study completion, an average of 1 year

  • Pain Intensity Visual Analog Scale (VAS)

    Through study completion, an average of 1 year

Study Arms (2)

Mulligan Consept Group (MCG)

EXPERIMENTAL
Other: Sustained Natural Apophyseal Glide (SNAG)

Neural Mobilization Group (NMG)

EXPERIMENTAL
Other: Sciatic Nerve Mobilization Exercises (SNME)

Interventions

In this intervention, participants will initially receive the SNAG technique targeting the L5-S1 lumbar segment. Participants will be seated on a treatment table with feet flat and knees at 90°. The therapist will position a specialized Mulligan belt around the L5-S1 segment and anchor it around their pelvis to generate a gentle traction force via controlled hip movement. While this force is applied, participants will perform active trunk flexion, holding the end-range position for 30 seconds. This movement will be repeated six times, constituting a 3-minute set. A total of 4 sets will be administered, with 2-minute rest periods between sets.

Mulligan Consept Group (MCG)

Participants will sit with hips and knees at 90° flexion, feet flat on the floor. The involved leg will be fully extended at the knee. In this position, the participant will be asked to perform ankle dorsiflexion and neck extension simultaneously (applying tension to the distal part of the sciatic nerve while relaxing the proximal part) and hold for 3 seconds. Next, the participant will plantarflex the ankle and flex the neck (tensioning the proximal end while relaxing the distal), again holding for 3 seconds. This 6-second sequence will be repeated 10 times per set. The exercise will be performed in 3 sets per leg, with 3-minute rests between sets.

Neural Mobilization Group (NMG)

Eligibility Criteria

Age20 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adults between the ages of 20 and 50,
  • Individuals describing non-specific sciatic pain characterized by unilateral low back pain accompanied by radiating symptoms to the leg,
  • Duration of pain longer than 12 weeks,
  • Presence of pain during the Slump Test and Straight Leg Raise Test,
  • No history of any physical therapy or intervention in the past month.

You may not qualify if:

  • Individuals diagnosed with herniated disc or spinal stenosis by a physician,
  • Physician-diagnosed secondary neurological conditions,
  • History of spinal surgery,
  • Individuals describing the origin of their pain as the lower back (without leg involvement),
  • Presence of neurological symptoms (e.g., foot drop, significant muscle weakness),
  • Serious medical conditions that may affect treatment or outcomes (e.g., cancer, infections, or inflammatory diseases),
  • Pregnancy or recent childbirth (within the past year),
  • Use of medications that may affect pain perception or mobility (e.g., opioids),
  • Inability to comply with the weekly treatment schedule.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clam Fizyoterapi Merkezi

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Çiçek Günday, Asst.Prof.

    Istinye University

    PRINCIPAL INVESTIGATOR
  • Sohiab Hassan Mohamed Wagdy Ahmed Elsayed Eladawi, Physiotherapist

    Istinye University

    STUDY CHAIR

Central Study Contacts

Sohiab Hassan Mohamed Wagdy Ahmed Elsayed Eladawi, Physiotherapist

CONTACT

Çiçek Günday, Asst.Prof.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Asst. Prof.

Study Record Dates

First Submitted

July 30, 2025

First Posted

September 8, 2025

Study Start

July 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

September 8, 2025

Record last verified: 2025-09

Locations